Zacks Research Issues Optimistic Forecast for PBH Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Equities researchers at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for shares of Prestige Consumer Healthcare in a report released on Tuesday, January 14th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $4.51 for the year, up from their previous estimate of $4.43. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.44 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q1 2026 earnings at $1.02 EPS, Q4 2026 earnings at $1.30 EPS, Q1 2027 earnings at $1.12 EPS, Q2 2027 earnings at $1.24 EPS and FY2027 earnings at $4.98 EPS.

Several other equities analysts have also recently commented on PBH. DA Davidson reaffirmed a "buy" rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Sidoti lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target for the company. in a research report on Monday, December 9th. Raymond James upgraded Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Jefferies Financial Group restated a "hold" rating and set a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Finally, StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Tuesday, January 7th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $85.25.

Prestige Consumer Healthcare Price Performance

PBH stock traded up $0.93 during mid-day trading on Thursday, reaching $78.13. 176,932 shares of the company traded hands, compared to its average volume of 278,003. The company has a fifty day moving average price of $80.59 and a 200-day moving average price of $74.39. Prestige Consumer Healthcare has a 52-week low of $58.22 and a 52-week high of $86.36. The company has a market capitalization of $3.86 billion, a P/E ratio of 18.97, a P/E/G ratio of 2.08 and a beta of 0.51. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting analysts' consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. During the same period last year, the company earned $1.07 earnings per share. The business's revenue for the quarter was down .9% on a year-over-year basis.

Insider Activity

In other news, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the transaction, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William P'pool sold 8,987 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the sale, the insider now owns 20,058 shares of the company's stock, valued at $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,810 shares of company stock valued at $3,187,300. Corporate insiders own 1.60% of the company's stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of large investors have recently bought and sold shares of the stock. Quest Partners LLC grew its holdings in shares of Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company's stock worth $30,000 after purchasing an additional 424 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company's stock worth $35,000 after acquiring an additional 433 shares during the last quarter. nVerses Capital LLC increased its position in shares of Prestige Consumer Healthcare by 200.0% in the third quarter. nVerses Capital LLC now owns 600 shares of the company's stock valued at $43,000 after acquiring an additional 400 shares during the period. Huntington National Bank raised its stake in shares of Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after acquiring an additional 181 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its holdings in shares of Prestige Consumer Healthcare by 7,112.5% during the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company's stock worth $83,000 after purchasing an additional 1,138 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.